Stock Events

Stock Events

Adynxx

$0

12

+$0+9,900% Monday 13:30

Statistics

Day High

0

Day Low

0

52W High

0

52W Low

0

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Dividends

0%Dividend Yield

Apr 19

$1.05

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

N/A

Earnings

29NovExpected

Q3 2021

Q4 2021

Q1 2022

Q2 2022

Q3 2022

Q2 2024

Q3 2024

0

0.33

0.67

1

Expected EPS

N/A

Actual EPS

N/A

Financials

-379.83%Profit Margin

Unprofitable

2013

2014

2015

2016

2017

2018

2.22MRevenue

-8.42MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADYX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a global pharmaceutical company that develops a wide range of medications, including pain management solutions that compete with Adynxx's non-opioid pain management products.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical segment Janssen, develops various drugs that can serve similar therapeutic areas as Adynxx, including pain management.

AbbVie has a strong portfolio in pain management and neuroscience, directly competing with Adynxx's focus on non-opioid pain therapies.

Novartis is a leading pharmaceutical company with a broad range of health solutions, including pain management drugs that compete with Adynxx's offerings.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries specializes in generic and specialty medicines, including pain management solutions that can compete with Adynxx's products.

Merck & Co., Inc. operates in various therapeutic areas, including pain management, potentially competing with Adynxx's pipeline.

Bristol-Myers Squibb

Bristol Myers Squibb offers a wide range of pharmaceutical products, including pain management solutions that could compete with Adynxx's focus areas.

Eli Lilly and Company has a diverse drug portfolio, including treatments for pain, which could compete with Adynxx's non-opioid pain management drugs.

Pacira BioSciences

Pacira Biosciences, Inc. specializes in non-opioid pain management solutions, directly competing with Adynxx's approach to pain management.

About

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Show more...

CEO

Mr. Richard Orr Esq., J.D.

Employees

6

Country

United States

ISIN

US00784D1037

Listings

0 Comments

Share your thoughts

FAQ

What is Adynxx stock price today?▼

The current price of ADYX is $0 USD — it has increased by +9,900% in the past 24 hours. Watch Adynxx stock price performance more closely on the chart.

What is Adynxx stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Adynxx stocks are traded under the ticker ADYX.

What is Adynxx revenue for the last year?▼

Adynxx revenue for the last year amounts to 2.22M USD.

What is Adynxx net income for the last year?▼

ADYX net income for the last year is -8.42M USD.

Does Adynxx pay dividends?▼

Yes, ADYX dividends are paid en. The last dividend per share was 1.05 USD. As of today, Dividend Yield (FWD)% is 0%.

How many employees does Adynxx have?▼

As of May 26, 2026, the company has 6 employees.

In which sector is Adynxx located?▼

Adynxx operates in the Health & Wellness sector.

When did Adynxx complete a stock split?▼

The last stock split for Adynxx was on April 18, 2019 with a ratio of 1:6.

Where is Adynxx headquartered?▼

Adynxx is headquartered in San Francisco, United States.